Efficacy of the Combination of Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours Abstract #1499

Introduction: Limited treatment options exist for patients (pts) with advanced pulmonary carcinoids (PC). Capecitabine-temozolomide (CAPTEM) has demonstrated significant efficacy in pts with pancreatic neuroendocrine tumours. However, its role in PC remains unexplored.
Aim(s): The aim of this study was to examine the efficacy of CAPTEM in advanced PC.
Materials and methods: Pts were treated with capecitabine 750mg/m2 BD day1-14 and temozolomide 200mg/m2 OD day10-14 of a 4-week cycle up to maximum of 6 cycles. All pts were treated at the Christie NHS Hospital from 3/2014 to 11/2015.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1356 Safety and Compliance of Capecitabine and Temozolomide in Patients with Advanced Neuroendocrine Tumours
Introduction: Capecitabine-temozolomide (CAPTEM) is a treatment option in patients (pts) with neuroendocrine tumours. Although efficacy data has been reported, no detailed safety information exists.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis
#3020 Outcomes Following Surgical Management of Pulmonary Carcinoids – A Tertiary Center Experience
Introduction: Pulmonary carcinoids are a rare type of malignant lung tumour. Surgery forms the mainstay of management when operable. However, there is paucity of data on conservative management and effective follow-up strategies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Dr Md Deloar Hoshen
#3015 Biopsy Specimen Diagnosis in Pulmonary Carcinoids, A Shot in the Dark
Introduction: Pulmonary carcinoids (PCs) are rare well-differentiated neuroendocrine tumors, which can be separated into typical carcinoid (TC) and atypical carcinoid (AC). Advised treatment for local carcinoid disease is surgical resection using lobectomy, while parenchymal saving strategies such as sub-lobar or endobronchial resection might be considered for TC. In general, pre-operative diagnosis using a (transbronchial/transthoracic) biopsy sample is performed to demonstrate malignancy. However, TC and AC classification can solely be performed on surgical resection specimens, which may challenge pre-operative treatment decisions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Drs Laura Moonen
#1518 Significance of Preoperative FDG-PET/CT Scan in Patients with Pulmonary Carcinoid Tumours
Introduction: FDG uptake on PET/CT scan has been shown to be of prognostic significance in patients (pts) with metastatic neuroendocrine tumours (NET).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Georgios Papaxoinis
#3053 The Splicing Machinery Is Dysregulated in Low Grade Pulmonary Neuroendocrine Tumors
Introduction: Alternative splicing dysregulation is increasingly regarded as a novel cancer hallmark influencing all key tumor features. We have shown that neuroendocrine tumors (NETs) overexpress aberrantly spliced variants of neuropeptides and receptors that increase tumor malignancy. More recently, we discovered that the splicing machinery is dysregulated in pituitary and pancreatic NETs. To date, the status of this machinery in low grade pulmonary NETs is largely unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Ricardo Blázquez-Encinas